Kamada Ltd. (KMDA) News

Kamada Ltd. (KMDA): $4.78

0.13 (-2.65%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add KMDA to Watchlist
Sign Up

Filter KMDA News Items

KMDA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KMDA News Highlights

  • KMDA's 30 day story count now stands at 3.
  • Over the past 1 day, the trend for KMDA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest KMDA News From Around the Web

Below are the latest news stories about KAMADA LTD that investors may wish to consider to help them evaluate KMDA as an investment opportunity.

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

Kedrion Biopharma, a leading global biopharmaceutical company that develops, manufactures and commercializes therapeutic products derived from blood plasma, announces the execution of a binding memorandum of understanding with Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB® US distribution agreement between the two companies.

Yahoo | December 7, 2023

KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Business Update On December 6, 2023, Kamada Ltd. (NASDAQ:KMDA) announced the execution of a binding memorandum of understanding with Kedrion for an amendment and extension of the company’s U.S. distribution agreement for Kedrab, a human rabies immune globulin indicated for the transient post-exposure prophylaxis of rabies

Yahoo | December 7, 2023

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Largest Commercial Agreement in Kamada’s History Becomes Effective in January 2024 and Includes $180 Million of Revenues to Kamada Over the First Four Years of the Eight Year TermFinancial Terms Reflect KEDRAB®'s Significant U.S. Market Share and Continued Growth Through the Eight Year TermAgreement Includes Potential Expansion of Kedrion’s Distribution of KEDRAB in Additional Territories Beyond the U.S.Kamada to Host a Conference Call and Live Webcast Today at 8:30 AM ET REHOVOT, Israel and HOB

Yahoo | December 6, 2023

KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On November 13, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the third quarter of 2023. Kamada reported revenues of $37.9 million, which was a 18% increase over the third quarter of 2022. The revenue consisted of $31.4 million from proprietary products and $6.5 million from the distribution

Yahoo | November 15, 2023

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Third Quarter 2023 Revenues were $37.9 Million Representing an 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26% Year-over-YearThird Quarter 2023 Adjusted EBITDA of $7.9 Million Representing a 31% Increase Year-over-Year; Nine Month 2023 Adjusted EBITDA of $17.7 Million, Up 67% Year-over-YearStrong Third Quarter Results and Positive Outlook for Fourth Quarter Support Reiteration of Fiscal Year 2023 Revenue and Adjusted EBITDA Guidance Multiple Recent Achievements wi

Yahoo | November 13, 2023

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2023, prior to the open of the U.S. financial markets on Monday, November 13, 2023. Kamada m

Yahoo | November 8, 2023

Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

Following Recent FDA Approval of Technology Transfer Process, CYTOGAM® Manufactured by Kamada at its Facility Now Available for Commercial Sales in U.S.New Clinical Data Highlighting Five-year Real-world Survival Benefits of High Risk CMV Mismatch Lung Transplant Patients Receiving CYTOGAM were Presented at IDWeek 2023Company Establishes Scientific Advisory Board Focused on U.S. Clinical Programs for CYTOGAM REHOVOT, Israel and HOBOKEN, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ

Yahoo | October 16, 2023

Kamada Provides Corporate Update on its Israel Operations

REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of product

Yahoo | October 10, 2023

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Funding Strengthens Kamada’s Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a lea

Yahoo | August 30, 2023

KMDA: 2Q23 Revenues up 59% YoY; Reiterates 2023 Revenue Guidance of $138 Million to $146 Million…

By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On August 22, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the second quarter of 2023. Kamada reported revenues of $37.4 million, which was a 59% increase over the second quarter of 2022. The revenue consisted of $30.9 million from proprietary products and $6.5 million from the distribution

Yahoo | August 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!